306 related articles for article (PubMed ID: 38275398)
21. Pancreatic ductal adenocarcinoma cells regulated the gemcitabine-resistance function of CAFs by LINC00460.
Zhu XX; Li JH; Ni X; Wu X; Hou X; Li YX; Li SJ; Zhao W; Yin XY
Cancer Sci; 2022 Nov; 113(11):3735-3750. PubMed ID: 36047966
[TBL] [Abstract][Full Text] [Related]
22. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches.
Ashrafizadeh M; Luo K; Zhang W; Reza Aref A; Zhang X
Environ Res; 2024 Jan; 240(Pt 2):117443. PubMed ID: 37863168
[TBL] [Abstract][Full Text] [Related]
23. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
24. GATA1 Promotes Gemcitabine Resistance in Pancreatic Cancer through Antiapoptotic Pathway.
Chang Z; Zhang Y; Liu J; Guan C; Gu X; Yang Z; Ye Q; Ding L; Liu R
J Oncol; 2019; 2019():9474273. PubMed ID: 31093285
[TBL] [Abstract][Full Text] [Related]
25. Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma.
Binenbaum Y; Fridman E; Yaari Z; Milman N; Schroeder A; Ben David G; Shlomi T; Gil Z
Cancer Res; 2018 Sep; 78(18):5287-5299. PubMed ID: 30042153
[TBL] [Abstract][Full Text] [Related]
26. AdipoRon and Pancreatic Ductal Adenocarcinoma: a future perspective in overcoming chemotherapy-induced resistance?
Sapio L; Ragone A; Spina A; Salzillo A; Naviglio S
Cancer Drug Resist; 2022; 5(3):625-636. PubMed ID: 36176754
[TBL] [Abstract][Full Text] [Related]
27. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
Dash S; Ueda T; Komuro A; Amano H; Honda M; Kawazu M; Okada H
Mol Cancer Res; 2023 May; 21(5):444-457. PubMed ID: 36757299
[TBL] [Abstract][Full Text] [Related]
28. The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2.
Kha ML; Hesse L; Deisinger F; Sipos B; Röcken C; Arlt A; Sebens S; Helm O; Schäfer H
Oncogene; 2019 Feb; 38(9):1461-1476. PubMed ID: 30302023
[TBL] [Abstract][Full Text] [Related]
29. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
Capula M; Perán M; Xu G; Donati V; Yee D; Gregori A; Assaraf YG; Giovannetti E; Deng D
Drug Resist Updat; 2022 Sep; 64():100864. PubMed ID: 36115181
[TBL] [Abstract][Full Text] [Related]
30. USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1.
Yang C; Zhu S; Yang H; Deng S; Fan P; Li M; Jin X
Am J Cancer Res; 2019; 9(8):1722-1733. PubMed ID: 31497353
[TBL] [Abstract][Full Text] [Related]
31. Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine.
Frappart PO; Hofmann TG
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987786
[TBL] [Abstract][Full Text] [Related]
32. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
33. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
34. The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.
Xie F; Huang M; Lin X; Liu C; Liu Z; Meng F; Wang C; Huang Q
Sci Rep; 2018 May; 8(1):8102. PubMed ID: 29802402
[TBL] [Abstract][Full Text] [Related]
35. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
[TBL] [Abstract][Full Text] [Related]
36. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
Panzeri V; Manni I; Capone A; Naro C; Sacconi A; Di Agostino S; de Latouliere L; Montori A; Pilozzi E; Piaggio G; Capurso G; Sette C
Mol Oncol; 2021 Feb; 15(2):579-595. PubMed ID: 33159833
[TBL] [Abstract][Full Text] [Related]
37. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
Gordon ER; Wright CA; James M; Cooper SJ
BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
[TBL] [Abstract][Full Text] [Related]
38. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
[TBL] [Abstract][Full Text] [Related]
39. Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition.
Abdalla MY; Ahmad IM; Rachagani S; Banerjee K; Thompson CM; Maurer HC; Olive KP; Bailey KL; Britigan BE; Kumar S
Transl Res; 2019 May; 207():56-69. PubMed ID: 30653942
[TBL] [Abstract][Full Text] [Related]
40. Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.
Lu C; Yang D; Sabbatini ME; Colby AH; Grinstaff MW; Oberlies NH; Pearce C; Liu K
BMC Cancer; 2018 Feb; 18(1):149. PubMed ID: 29409480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
